CompanyZURANasdaqLa Jolla, CA

Zura Bio Inc

Zura Bio develops dual-pathway antibodies for autoimmune and inflammatory diseases.

SEC EDGAR ClinicalTrials.gov zurabio.com

424B3Sep 25Latest SEC filing

Aug 11Latest story

August 2026

Zura Bio reports Q2 2026 results, completes enrollment in two tibulizumab trials

Aug 11Clinical readouttibulizumab Zura Bio Inc